Highline Capital Management, L.P. Solid Biosciences Inc. Transaction History

Highline Capital Management, L.P.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$21.32 - $46.34 $1.17 Million - $2.55 Million	-55,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$36.35 - $51.7 $93,964 - $133,644	2,585 Added 4.93%	55,000 $2.6 Million
Q2 2018 Aug 14, 2018	BUY	$7.33 - $43.15 $384,201 - $2.26 Million	52,415 New	52,415 $1.87 Million

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $41.9M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Highline Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Highline Capital Management, L.P. with notifications on news.